ARCHIVES

NCI Plans Preclinical Studies Of Endoxifen, A Tamoxifen Metabolite.

This article is from The Cancer Letter archive.

Vol. 35 No. 31 | August 7, 2009

Download PDF Visit The Full Archive

Related Articles

No Cancer Letter for Two Weeks

August 13, 1993

Iressa Shrinks Some Lung Tumors, Reduces Symptoms In Phase II Trial

June 28, 2002

In Brief: Jane Henney, Former NCI Deputy Director, Named FDA Deputy Commissioner For Operations

November 15, 1991

NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.

May 4, 2001

NCI-Approved Group, Center Clinical Trials Listed

May 25, 2007

NCI Advisory Group, Other Cancer Meetings

July 29, 1983